Recursion Pharmaceuticals AI Stock Analysis
Want to see RXRX full AI Analyst Report?
Recursion Pharmaceuticals (RXRX) AI Stock Analysis
Recursion Pharmaceuticals
(NASDAQ:RXRX)
RXRX scores as a balanced but higher-risk biotech: strong earnings-call momentum (pipeline progress, partnership inflows, extended runway, and reduced expense guidance) is offset by very weak profitability and significant ongoing cash burn in the financials. Technical signals are neutral-to-slightly weak, and valuation is difficult to support on a negative P/E with no dividend yield provided.
Recursion Pharmaceuticals Key Performance Indicators (KPIs)
Revenue by SegmentBreaks down revenue by different business units or product lines, highlighting which areas are driving growth and which may need strategic adjustments. This insight helps assess the company's diversification and dependency on specific segments.
Operating revenue is highly lumpy and dominates total revenue, reflecting milestone and collaboration cash recognition rather than recurring product sales; grant revenue is immaterial and episodic. Management’s disclosure of >$500M in realized partnership inflows (including >$260M from Roche‑Genentech) and ongoing milestone opportunities explains recent spikes and supports the cash runway, but also makes top‑line growth timing‑dependent. For investors, prioritize the cadence of partnership milestones and clinical/IND triggers that unlock payments, and watch execution/timing risk rather than quarter‑to‑quarter revenue volatility.
Recursion Pharmaceuticals (RXRX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.69B
- Dividend Yield
- ―
- Average Volume (3M)
- 23.66M
- Price to Earnings (P/E)
- -3.0
- Beta (1Y)
- 3.09
- Revenue Growth
- 56.18%
- EPS Growth
- 50.69%
- Country
- US
- Employees
- 600
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Recursion Pharmaceuticals Business Overview & Revenue Model
Company Description
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines te...
How the Company Makes Money
Recursion primarily makes money through (1) collaboration and partnership revenue with pharmaceutical partners and (2) its own drug discovery and development pipeline, with potential future revenues from product sales if its candidates are approved....
Recursion Pharmaceuticals Earnings Call Summary
The call was strongly positive, led by encouraging early clinical activity for REC-4881 and REC-1245, progress across Sanofi, Roche, and Genentech partnerships, more than $535 million in partner cash inflows, substantial platform productivity gains, a $200 million financing, and runway into 2029. The main negatives were treatment-related adverse events, dose-limiting toxicities at higher REC-1245 doses, the early and investigational nature of the clinical data, and the need for further regulatory and registrational validation. Highlights significantly outweighed the lowlights.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Recursion expects cash runway to extend into 2029; 2026 full-year cash operating expense guidance is less than $375 million, excluding partnership inflows and one-time expenses, and in 2027 cash operating expenses are expected to be less than $360 million. Sanofi’s optioned candidate is expected to begin phase I in 2027, with potential for additional partner milestones in 2027; for REC-4881, the company is targeting initiation of a registrational study in the second half of 2027, based on regulatory alignment, and expects to update FDA conversations and generate additional phase II data; for REC-1245, preliminary data from the endometrial expansion cohort are expected in the second half of 2027, along with additional clinical readouts from the rest of the portfolio.
Recursion Pharmaceuticals Financial Statement Overview
Summary
Revenue is growing strongly (+24.386% TTM), but profitability and cash generation are very weak (gross margin ~10.7%, EBIT margin ~-703%, negative operating cash flow and free cash flow around -$311M/-$314M TTM). The balance sheet is a relative strength with low leverage (debt-to-equity ~0.08), yet persistently deep losses and lumpy, milestone-driven revenue increase dilution and execution risk.
Income Statement
24NegativeBalance Sheet
63PositiveCash Flow
28Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 68.23M | 74.68M | 58.84M | 43.88M | 39.68M | 10.00M |
| Gross Profit | 7.33M | -46.27M | 13.60M | 1.29M | -8.59M | 10.00M |
| EBITDA | -405.71M | -559.38M | -426.72M | -307.63M | -227.66M | -175.12M |
| Net Income | -475.67M | -644.76M | -463.66M | -328.07M | -239.48M | -186.48M |
Balance Sheet | ||||||
| Total Assets | 1.22B | 1.47B | 1.45B | 653.70M | 701.29M | 610.35M |
| Cash, Cash Equivalents and Short-Term Investments | 549.85M | 743.29M | 594.35M | 391.56M | 549.91M | 516.56M |
| Total Debt | 74.70M | 77.97M | 108.49M | 50.67M | 51.01M | 11.48M |
| Total Liabilities | 315.90M | 343.26M | 413.82M | 190.26M | 215.48M | 67.41M |
| Stockholders Equity | 905.81M | 1.13B | 1.03B | 463.44M | 485.81M | 542.94M |
Cash Flow | ||||||
| Free Cash Flow | -314.48M | -378.28M | -372.87M | -299.74M | -120.88M | -198.41M |
| Operating Cash Flow | -310.53M | -371.81M | -359.17M | -287.78M | -83.52M | -158.61M |
| Investing Cash Flow | -3.95M | -16.87M | 260.06M | -10.23M | 193.25M | -271.74M |
| Financing Cash Flow | 210.41M | 521.53M | 304.12M | 140.13M | 154.34M | 458.54M |
Recursion Pharmaceuticals Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RXRX, the sentiment is Negative. The current price of 2.72 is below the 20-day moving average (MA) of 3.64, below the 50-day MA of 3.75, and below the 200-day MA of 3.46, indicating a bearish trend. The MACD of -0.21 indicates Positive momentum. The RSI at 33.32 is Neutral, neither overbought nor oversold. The STOCH value of 7.10 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RXRX.
Recursion Pharmaceuticals Risk Analysis
Recursion Pharmaceuticals disclosed 107 risk factors in its most recent earnings report. Recursion Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksRecursion Pharmaceuticals Peers Comparison
Overall Rating
NRIX61Neutral
RXRX54Neutral
DNLI54Neutral
GLUE54Neutral
ABSI50Neutral
GENB41.6Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 61Neutral | $1.56B | 5.67 | 49.34% | ― | 738.76% | ― | |
| 54Neutral | $1.70B | -2.99 | -47.85% | ― | 56.18% | 50.69% | |
| 54Neutral | $2.89B | -10.29 | -33.98% | ― | ― | 40.59% | |
| 54Neutral | $775.03M | -5.28 | -30.14% | ― | -61.26% | -597.59% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | $1.31B | -9.50 | -60.84% | ― | -47.18% | 12.12% | |
| 42Neutral | $1.27B | -4.15 | -146.07% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| RXRX | Recursion Pharmaceuticals, Inc | 2.72 | -1.13 | -29.35% | |
| DNLI | Denali Therapeutics | 18.00 | 0.84 | 4.90% | |
| NRIX | Nurix Therapeutics, Inc. | 14.24 | -1.09 | -7.11% | |
| GLUE | Monte Rosa Therapeutics, Inc. | 9.07 | -4.45 | -32.91% | |
| ABSI | Absci Corp. | 7.58 | 4.81 | 173.65% | |
| GENB | Generate Biomedicines, Inc. | 9.84 | -2.81 | -22.21% |
Recursion Pharmaceuticals Corporate Events
Recursion Reports Clinical Progress as Sanofi Options First Candidate
PositiveOn November 2, 2026, Recursion, a clinical-stage company pioneering AI-enabled drug discovery and development, reported third-quarter results and clinical updates. Phase 2 data showed REC-4881 produced deep, durable reductions in gastrointestinal pol...
Recursion Pharmaceuticals prices offering and advances pipeline
PositiveOn Oct. 15, 2026, Recursion Pharmaceuticals moved to strengthen its balance sheet and pipeline by pricing an underwritten public offering of 61.54 million Class A shares at $3.25, for expected gross proceeds of about $200 million before fees. All sha...
Recursion, Tempus Expand AI and RNA Collaboration Agreements
PositiveOn September 15, 2026, Recursion Pharmaceuticals amended its long-term data and AI collaboration with Tempus AI, extending the master agreement term from five to six years and waiving its prior right to terminate for convenience. The amendment lowers...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 04, 2026
